Adenoassociated virus (AAV) is often the vector of choice for gene therapies due to their low immunogenicity, ability to promote long-term gene expression, and capsid tropism-dependent tissue specificity. Representing around 37% of the current advanced therapies market, there is an ongoing demand for robust quality lot release programs capable of supporting the large patient cohorts …Read More >
TiCARos Therapeutics has leveraged the expertise of their team of immunologists from Seoul National University, College of Medicine to develop a promising pipeline of nextgeneration immunotherapies for intractable haematologic malignancies and advanced solid tumours. TiCARos’ mission is to create medication based on science. TiCARos was founded by two leading T cell immunologists, who have built …Read More >
New state-of-the-art advanced therapies testing laboratories provide additional capacity for the growing cell and gene therapy industry. WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, has opened its advanced therapies testing facility at 400 Rouse Boulevard in Philadelphia’s Navy Yard. The new facility, which includes 140,000 square feet laboratories, will further …Read More >
Adeno-associated virus (AAV) is often the vector of choice for gene therapies; in fact, AAV represents around 37% of the current advanced therapies market. And when it comes to manufacturing AAV for in vivo gene therapies, developers must pursue triplicate goals of quality, quantity, and speed. At OXGENE and WuXi ATU, our ambition is to …Read More >
The majority of adeno-associated viral (AAV) vector produced globally is manufactured using triple transfection. But plasmid-based AAV manufacture has drawbacks – the need to transfect cells results in a process which cannot be truly scalable, and yield and particle infectivity could be improved upon. Tetracycline Enabled Self Silencing Adenovirus (TESSA) technology utilizes adenovirus to manufacture …Read More >